Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Matthew Stargardter, Ali McBride, Jon Tosh, Rameet Sachdev, Mo Yang, Apoorva Ambavane, Madhav Mittal, Helene Vioix & Frank Xiaoqing Liu. (2021) Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States. Journal of Medical Economics 24:1, pages 816-827.
Read now
Read now
Huamao M. Lin, Xiaoyun Pan, Peijie Hou, Hui Huang, Yanyu Wu, Kaili Ren & Mohammad Jahanzeb. (2020) Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. Journal of Medical Economics 23:8, pages 894-901.
Read now
Read now
Articles from other publishers (7)
Mo Yang, Helene Vioix, Rameet Sachdev, Matthew Stargardter, Jon Tosh, Boris M. Pfeiffer & Paul K. Paik. (2023) Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping. Value in Health 26:4, pages 487-497.
Crossref
Crossref
Akhil Kapoor, Vanita Noronha, Vijay Patil, Nandini Menon, Amit Joshi, Amit Kumar, Ajay Kumar Singh, Abhishek Mahajan, Amit Janu, Rajiv Kumar, Trupti Pai, Anuradha Chougule, Omshree Shetty & Kumar Prabhash. (2023) Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings. JTO Clinical and Research Reports 4:1, pages 100443.
Crossref
Crossref
Yanyu Wu, Kaili Ren, Yin Wan & Huamao M Lin. (2022)
Economic burden in patients with anaplastic lymphoma kinase (
ALK
)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors
. Journal of Oncology Pharmacy Practice, pages 107815522211261.
Crossref
Crossref
Andrea Spini, Giulia Hyeraci, Claudia Bartolini, Sandra Donnini, Pietro Rosellini, Rosa Gini, Marina Ziche, Francesco Salvo & Giuseppe Roberto. (2021) Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data. International Journal of Environmental Research and Public Health 18:14, pages 7679.
Crossref
Crossref
Mohammad Jahanzeb, Huamao M. Lin, Xiaoyun Pan, Yu Yin, Yanyu Wu, Beth Nordstrom & Mark A. Socinski. (2020)
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for
ALK+
Non-Small Cell Lung Cancer
. The Oncologist 25:10, pages 867-877.
Crossref
Crossref
Ajaikumar B Kunnumakkara, Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Nand Kishor Roy, Krishan Kumar Thakur, Kishore Banik, Mehdi Shakibaei, Subash C Gupta & Bharat B Aggarwal. (2019) Cancer drug development: The missing links. Experimental Biology and Medicine 244:8, pages 663-689.
Crossref
Crossref
Salman Otoukesh, Tiffany Sanchez, Saied Mirshahidi, Desiree Wallace & Hamid Mirshahidi. (2019) ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase–positive non-small cell lung Cancer: A clinical perspective. Cancer Treatment and Research Communications 20, pages 100149.
Crossref
Crossref